Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer.
作者信息
Welch H Gilbert, Mogielnicki Juliana
机构信息
VA Outcomes Group (111B), Department of Veterans Affairs, White River Junction, VT 05009 USA.
出版信息
BMJ. 2002 May 4;324(7345):1088-92. doi: 10.1136/bmj.324.7345.1088.
Abstract
摘要
相似文献
1
Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer.
BMJ. 2002 May 4;324(7345):1088-92. doi: 10.1136/bmj.324.7345.1088.
2
Health insurance: coverage of autologous bone marrow transplantation for breast cancer.
Oncology (Williston Park). 1996 Sep;10(9):1329-32, 1337-8, 1340 passim.
3
Universal coverage and individual mandate in Switzerland: lessons for Massachusetts.
Issue Brief (Mass Health Policy Forum). 2007 Jun 22(33):1-16.
4
What is the method to their "madness?" Experimental treatment exclusions in health insurance policies.
J Contemp Health Law Policy. 1997 Spring;13(2):613-36.
5
Cancer coverage. Why are insurers paying for this "experimental" therapy?
Med Econ. 1996 Sep 9;73(17):38.
6
The injustice of infertility insurance coverage: an examination of marital status restrictions under state law.
Albany Law Rev. 2012;75(4):2133-49.
7
ABMT and breast cancer.
Healthplan. 1999 Jul-Aug;40(4):30-3, 35-7.
8
Experimental medical treatments: who should decide coverage?
Seattle Univ Law Rev. 1997 Winter;20(2):451-87.
9
The American approach to health insurance. 1934.
Milbank Q. 2005;83(4):537-47. doi: 10.1111/j.1468-0009.2005.00391.x.
10
The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer.
Health Aff (Millwood). 2001 Sep-Oct;20(5):101-17. doi: 10.1377/hlthaff.20.5.101.
引用本文的文献
1
Off-label policy through the lens of trazodone usage and spending in the United States.
Health Aff Sch. 2025 Jun 11;3(7):qxaf114. doi: 10.1093/haschl/qxaf114. eCollection 2025 Jul.
2
Chitosan Nanoparticles for Targeted Cancer Therapy: A Review of Stimuli-Responsive, Passive, and Active Targeting Strategies.
Int J Nanomedicine. 2024 Aug 15;19:8373-8400. doi: 10.2147/IJN.S472433. eCollection 2024.
3
A modest proposal for a new way forward for clinical research: Involve insurance companies.
Int Forum Allergy Rhinol. 2022 May;12(5):685-689. doi: 10.1002/alr.22980. Epub 2022 Feb 9.
4
Developing a Prognostic Information System for Personalized Care in Real Time.
EGEMS (Wash DC). 2019 Mar 25;7(1):2. doi: 10.5334/egems.266.
5
Randomized Trials of Proton Therapy: Why They Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced Technologies to Diagnose and Treat Cancer.
J Clin Oncol. 2018 Aug 20;36(24):2461-2464. doi: 10.1200/JCO.2018.77.7078. Epub 2018 Jul 9.
6
Alleviation of Side Effects and Distress in Breast Cancer Patients by Cognitive-Behavioral Interventions: A Systematic Review and Meta-analysis.
J Clin Psychol Med Settings. 2018 Dec;25(4):335-355. doi: 10.1007/s10880-017-9526-7.
7
Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders.
BMC Med Ethics. 2015 Nov 4;16(1):75. doi: 10.1186/s12910-015-0069-x.
8
The role of professional societies in limiting indication creep.
J Gen Intern Med. 2015 Feb;30(2):249-52. doi: 10.1007/s11606-014-2980-0. Epub 2014 Aug 5.
9
Reference pricing with evidence development: a way forward for proton therapy.
J Clin Oncol. 2014 May 20;32(15):1540-2. doi: 10.1200/JCO.2014.55.6613. Epub 2014 Apr 21.
10
Research misconduct in low- and middle-income countries.
PLoS Med. 2013;10(3):e1001315. doi: 10.1371/journal.pmed.1001315. Epub 2013 Mar 26.
本文引用的文献
1
Business thrives on unproven care, leaving science behind: a special report.
N Y Times Web. 1999 Oct 3:A1, A40-41.
2
Women resist trials to test marrow transplants.
N Y Times Web. 1995 Feb 15:C8.
3
High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study.
Lancet. 2000 Mar 18;355(9208):999-1003. doi: 10.1016/S0140-6736(00)90024-2.
4
High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer.
N Engl J Med. 2000 Apr 13;342(15):1119-20. doi: 10.1056/NEJM200004133421508.
5
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
N Engl J Med. 2000 Apr 13;342(15):1069-76. doi: 10.1056/NEJM200004133421501.
6
Researchers struggle with trials of stem-cell transplants for breast cancer.
JAMA. 1997 Jun 18;277(23):1827-9.
7
The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer.
CA Cancer J Clin. 1996 May-Jun;46(3):142-64. doi: 10.3322/canjclin.46.3.142.
8
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
J Clin Oncol. 1993 Jun;11(6):1132-43. doi: 10.1200/JCO.1993.11.6.1132.
9
Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
N Engl J Med. 1994 Feb 17;330(7):473-7. doi: 10.1056/NEJM199402173300707.
10
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
J Clin Oncol. 1995 Oct;13(10):2483-9. doi: 10.1200/JCO.1995.13.10.2483.
Zotero 插件